An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis:a multicentre, double-blind, placebo-controlled phase 2b study
Publikationen
- 2023
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply
Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E. & Furue, M., 18.11.2023, in: LANCET. 402, 10415, S. 1834Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Kommentar › Forschung